Details for New Drug Application (NDA): 204766
✉ Email this page to a colleague
NDA 204766 describes EFAVIRENZ, which is a drug marketed by Aurobindo Pharma, Aurobindo Pharma Ltd, Cipla, Hetero Labs Ltd Iii, Macleods Pharms Ltd, Mylan, Strides Pharma, Hetero Labs Ltd V, Laurus, and Teva Pharms Usa, and is included in twenty-one NDAs. It is available from eight suppliers. Additional details are available on the EFAVIRENZ profile page.
The generic ingredient in EFAVIRENZ is efavirenz; lamivudine; tenofovir disoproxil fumarate. There are twenty-six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the efavirenz; lamivudine; tenofovir disoproxil fumarate profile page.
The generic ingredient in EFAVIRENZ is efavirenz; lamivudine; tenofovir disoproxil fumarate. There are twenty-six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the efavirenz; lamivudine; tenofovir disoproxil fumarate profile page.
Suppliers and Packaging for NDA: 204766
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| EFAVIRENZ | efavirenz | TABLET;ORAL | 204766 | ANDA | Cipla USA Inc. | 69097-301 | 69097-301-02 | 30 TABLET, FILM COATED in 1 BOTTLE (69097-301-02) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 600MG | ||||
| Approval Date: | Jun 15, 2018 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
